DERMATOLOGICAL CONDITIONS

2017 Therapeutic Update

Stephen Schleicher, MD

DermDox Center for Dermatology

Hazleton, PA

from to

Pharmaceutical Activities

• Speaker: Aqua, Celgene, Pfizer

• Principal Investigator:

• Allergan ♦ Amgen ♦ Dr Reddys ♦Exeltis ♦

Ferndale ♦ Galderma ♦ Genentech ♦ Glaxo ♦

Helix BioMedix ♦ Intraderm ♦Lilly ♦ Oculus ♦

♦ Quinnova ♦Taro ♦ Pfizer ♦ Valeant

ABSCESSES

ALOPECIA AREATA

ALOPECIA AREATA: LEGS

ALOPECIA AREATA TREATMENT

Traditional:

Steroids:topical/intralesional

Investigational: JAK inhibitors

ATOPIC DERMATITIS

ECZEMA AFFECTS OVER 3%

OF THE US POPULATION

What is Eczema/Atopic Dermatitis ?

Chronic itchy rash of unknown origin

Related to hay fever and asthma

NUMULAR ECZEMA

TREATMENT

TRADITIONAL:

Steroids

Calcineurin inhibitors (Elidel/Protopic)

Cyclosporine

NEW:

Eucrisa [crisaborole] (approved 2016)

Dupixent [Dupilumab] (approved 2017)

CAT FLEAS

CONTACT DERMATITIS

CONTACT DERMATITIS

POISON

IVY

CONTACT DERMATITIS

NICKEL

CONTACT DERMATITIS

NEOMYCIN

Shoe Dermatitis

CONTACT DERMATITIS

DIAGNOSIS

PATCH TEST

POSITIVE PATCH TEST

POSITIVE PATCH TEST

TREATMENT

STEROIDS:

FUNGAL INFECTIONS

Tinea corporis

Tinea pedis

Onychomycosis

Fungal Infection Treatment

ORAL:

Griseofulvin/terbinafine/itraconazole/fluconazole

TOPICALS:

Latest: Kerydin (tavaborole) - approved 2014

Jublia (efinaconazole) – approved 2014

Luzu (luzuconazole) - approved 2013

NEW NEGATIVE

HOT: LASERS + TOPICALS FOR

ONYCHOMYCOSIS

LICHEN PLANUS

LICHEN PLANUS THERAPY

TRADITIONAL: STEROIDS

PSORIASIS

WHAT’S NEW: THE REVOLUTION

CONTINUES -

Otezla(apremilast)

Approved 2014

Cosentyx(sekukinumab)

Approved 2015

Taltz(ixekizumab)

Approved 2016

Siliq(brodalumab)

Approved 2017

Stasis Dermatitis

Cellulitis

JAMA Dermatol. 2017

Cross-sectional study using patients admitted from the emergency

department (ED) of a large urban hospital with a diagnosis of lower extremity

cellulitis

Of 259 patients, 79 (30.5%) were misdiagnosed with cellulitis, and 52 of

these

misdiagnosed patients were admitted primarily for the treatment of cellulitis.

We estimate cellulitis misdiagnosis leads to 50 000 to 130 000 unnecessary

hospitalizations and $195 million to $515 million in avoidable health care spending.

Unnecessary antibiotics and hospitalization for misdiagnosed cellulitis are

projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium

difficile infections, and 2 to 6 cases of anaphylaxis annually.

VERRUCAE (WARTS)